We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Diurnal Group Plc | LSE:DNL | London | Ordinary Share | GB00BDB6Q760 | ORD GBP0.05 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 27.30 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMDNL
Diurnal Group PLC
07 June 2022
7 June 2022
Diurnal Group plc
("Diurnal" or the "Company")
Diurnal to present research into the treatment of congenital adrenal hyperplasia at ENDO 2022
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, will be presenting research findings on the treatment and management of congenital adrenal hyperplasia (CAH) at this year ' s American Endocrine Society meeting, ENDO 2022, which will be taking place between 11-14 June 2022 in Atlanta, USA.
Over the four-day meeting, the following topics will be presented:
-- Comparison of prednisolone versus hydrocortisone modified-release hard capsules (Efmody(R) ) in the treatment of CAH .
-- A de novo model for measuring long-term health effects of hydrocortisone modified-release hard capsules in adult and adolescent patients with classic CAH.
CAH occurs when the production of cortisol from the adrenal gland is limited due to a genetic deficiency. CAH is associated with over-production of male sex hormones resulting in ambiguous genitalia at birth, precocious sexual development, infertility in men and women, and increased mortality through adrenal crisis.
Around 450,000 people globally are estimated to be living with a CAH disorder yet there is no standard treatment. Instead, a variety of steroids are used but data shows around two thirds of people living with CAH still have problems with disease control[i].
Richard Bungay, Interim Chief Executive Officer of Diurnal commented:
"These presentations at ENDO follow our very well attended presentations at the European Congress of Endocrinology meeting in Europe last month. Diurnal is committed to supporting research into diseases of cortisol deficiency and developing solutions to support patients with these life-long disorders. The interest we have received from the world's leading endocrinologists demonstrates the progress we are making in the treatment and management of diseases of cortisol deficiency."
For further information, please visit www.diurnal.co.uk or contact: +44 (0)20 3727 Diurnal Group plc 1000 Richard Bungay, Interim Chief Executive Officer Panmure Gordon (UK) Limited (Nominated Adviser +44 (0)20 7886 and Joint Corporate Broker) 2500 Corporate Finance: Freddy Crossley, Emma Earl Corporate Broking: Rupert Dearden Stifel Nicolaus Europe Limited (Joint Corporate +44 (0) 20 7710 Broker) 7600 Healthcare Investment Banking: Nicholas Moore, Samira Essebiyea, William Palmer-Brown Corporate Broking: Nick Adams, Nick Harland +44 (0)20 3727 FTI Consulting (Media and Investor Relations) 1000 Simon Conway Victoria Foster Mitchell Alex Davis +44 (0) 173 782 Vane Percy & Roberts (Medical Communications) 1890 Simon Vane Percy
Notes to Editors
About Diurnal Group plc
Diurnal Group plc is a European, UK-headquartered, specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism and hypothyroidism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.
For further information about Diurnal, please visit www.diurnal.com
Date of Preparation: June 2022 Code: CORP-GLO-0039
[i] Mallappa, A., Merke, D.P. Management challenges and therapeutic advances in congenital adrenal hyperplasia. Nat Rev Endocrinol 18, 337-352 (2022). https://doi.org/10.1038/s41574-022-00655-w
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NRAKZGGVMNMGZZM
(END) Dow Jones Newswires
June 07, 2022 08:00 ET (12:00 GMT)
1 Year Diurnal Chart |
1 Month Diurnal Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions